Though the peptide was shown to induce peptide-specific perforin-positive CD8+ T-cells from PBMCs of cancer patients, it remains to be determined whether the peptide-specific T-cells have a capability of killing cancer cells in an HLA-A24-restricted manner. Here, PRF1 is linked to cancer.